Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma

Inclusion Criteria: * Histologically confirmed lymphoma; * Patients are scheduled to receive cytarabine-based chemotherapy including Ara-C at dose of 4g/m2. * Eastern Cooperative Oncology Group (ECOG) of 0-1; * Proper functioning of the major organs: 1) The absolute value of neutrophils (\>1.5×10\^9/L); platelet count (\> 100×10\^9/L); Hemoglobin (\> 90 g/L); 2) Serum total bilirubin \< 1.5 times ULN; Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) \< 3 times ULN;3) Serum creatinine \<1.5 times Upper Limit Normal (ULN) ; 4) Coagulation function: International Normalized Ratio (INR), Prothrombin Time (PT)\< 1.5 times ULN * Able to use oral drugs * Patients volunteer to sign an informed consent * Life expectancy \> 3 months; * Contraceptives are used Exclusion Criteria: * Thrombocytopenia unrelated to chemotherapy during six months before screening, including but not limited to hypersplenism, infection and hemorrhage. * In addtion to CIT caused by lymphoma and chemotherapy,patients also suffer from other blood diseases including ALL, AML, myeloid neoplasms, MDS, myeloproliferative disorders, MM; * A thrombosis of a coronary artery or vein developed during three months before screening; * Haemorrhage with severe clinical symptoms, such as gastrointestinal and cerebral hemorrhage; * Platelet transfusion during two days before randomization; * Allergic to avatrombopag; * Participation in any other research about novel agents or devices; * Pregnant or breastfeeding women; * Researchers consider it unsuitable for patients to participate in this study.